[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"early-stage-non-small-cell-lung-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:early-stage-non-small-cell-lung-cancer":67},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100659878","phase-2-a-study-to-assess-the-safety-and-tolerability-of-pumitamig-based-therapy-administered-before-surgery-in-participants-with-early-stage-non-small-cell-lung-cancer-rosetta-lung-220-100659878",false,"NCT07871214","A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)","ROSETTA Lung-220: A Phase 2, Open-Label, Multicenter, Multi-Arm Platform Study Evaluating Pumitamig and Other Novel Neoadjuvant Regimens in Participants With Resectable, Early-Stage (IIA to IIIB) Non-Small Cell Lung Cancer","Inclusion Criteria\n\n* Participants must have newly diagnosed, previously untreated participants with histologically confirmed non-small cell lung cancer (NSCLC) (squamous or non-squamous histology); resectable Stage IIA to IIIB (N2) disease (American Joint Committee on Cancer (AJCC) 9th edition).\n* Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n* Participants must have an evaluable programmed death-ligand 1 (PD-L1) expression.\n\nExclusion Criteria\n\n* Participants must not have unresectable disease, N3 nodal involvement, or any evidence of distant metastatic disease (M1) at baseline assessment (suspected or confirmed).\n* Participants must not have active, known autoimmune disease.\n* Participants must not have significant cardiovascular impairment as evidenced by uncontrolled hypertension (despite optimal medical treatment), congestive heart failure, active coronary disease (within 6 months prior to randomization), ventricular arrhythmias or major thrombotic or embolic events.\n* Participants must not have advanced\u002Fclinically significant lung disease (within 6 months prior to randomization) or history of interstitial lung disease (ILD) or pneumonitis requiring treatment with systemic steroids (≥ Grade 2), or who have current or suspected ILD or pneumonitis.\n* Participants must not have significant risk of bleeding or history of major hemorrhagic events (including gastrointestinal (GI) hemorrhage or hemorrhagic stroke).\n* Participants must not have GI or non-GI fistula, GI perforation, or intra-abdominal abscess.\n* Participants must not have prior systemic anticancer therapy, radiotherapy, or investigational therapy for NSCLC or contraindication to curative-intent surgery or study-specified chemotherapy.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.","ALL","18 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The purpose of this study is to assess the safety, tolerability, and surgical feasibility of preoperative Pumitamig-based therapy and other molecules in resectable, Early-Stage Non-Small Cell Lung Cancer",[26],"Early-Stage Non-Small Cell Lung Cancer",[28],"Participants with Stage IIA to IIIB considered surgical candidates","NOT_YET_RECRUITING","2026-10-07",{"date":32,"type":33},"2026-10-13","ACTUAL",{"date":35,"type":20},"2026-11-30",{"date":37,"type":20},"2028-03-15",{"name":39,"class":40},"Bristol-Myers Squibb","INDUSTRY",50,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":66},"100327722","phase-1-safety-trial-of-antimicrobial-therapy-and-precision-radiation-therapy-in-patients-with-oligoprogressive-non-small-cell-lung-cancer-100327722","NCT03546829","Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer","Randomized Pilot Inclusion\n\n* Patients planned to receive Stereotactic Body Radiotherapy (SBRT) to a biopsy-proven or clinically-suspected NSCLC\n* Age \\>18 years' old\n* Patient capable of giving informed consent\n\nRandomized Pilot Exclusion\n\n* Use of antibiotics, antifungal, antivirals or antiparasitics during the 4 weeks prior to registration\n* Active infection with oral temperature \\>100°F\n* Use of corticosteroids, methotrexate or immunosuppressive drugs during the 4 weeks prior to registration\n* Use of chemotherapy during the 4 weeks prior to radiotherapy or during radiotherapy. Chemotherapy cannot begin before the collection of the 30-day post treatment sample (S4).\n* Documented history of HIV, HBV or HCV\n* Active uncontrolled gastrointestinal disorders such as inflammatory bowel disease, moderate\u002Fsevere irritable bowel syndrome, persistent, infectious gastroenteritis, colitis or gastritis, persistent or chronic diarrhea of unknown etiology, Clostridium Difficile infection (within 2 years of lung cancer diagnosis) or Helicobacter Pylori infection (untreated)\n* Major surgery of the GI tract, with the exception of cholecystectomy and appendectomy, in the past five years. Any major bowel resection at any time\n* Patients on anti-diarrheal medications\n* Patients on probiotics\n\nSafety Trial Inclusion\n\n* Patients planned to receive precision hypofractionated radiation (SBRT or an ablative dose of radiation is used if SBRT is not appropriate or if insurance does not approve - i.e. \\> 30 Gy in 10 fraction equivalent) to all sites of oligoprogressive NSCLC who progressed after 1st line systemic therapy for metastatic disease which included immunotherapy or a tyrosine kinase inhibitors (TKI) for NSCLC\n* The number of sites of progression are \\\u003C 5 sites.\n* Age \\>18 years' old\n* Patient capable of giving informed consent\n\nSafety Trial Exclusion\n\n* Evidence of untreated CNS or leptomeningeal disease\n* Use of antibiotics, antifungal, antivirals or antiparasitics during the 4 weeks prior to registration\n* Active infection with oral temperature \\>100°F\n* Use of oral corticosteroids, methotrexate or immunosuppressive drugs during the 4 weeks prior to registration\n* Use of chemotherapy during the 4 weeks prior to radiotherapy or during radiotherapy. Chemotherapy cannot begin before the collection of the 30-day post treatment sample (S3).\n* Documented history of HIV, HBV or HCV\n* Patients on daily anti-diarrheal medications\n* Use of probiotics during the 4 weeks prior to radiotherapy or during radiotherapy",{"count":49,"type":20},10,[51],"PHASE1","The first phase of this study was an open label, randomized pilot study. Enrollment for this phase is now complete.\n\nThe second phase is a single arm phase 1 safety study. Patients planned to undergo precision hypofractionated radiation to all sites of oligoprogression will receive vancomycin for 1 week before RT and for 1 month after start of RT, and asked to provide stool and blood samples as outlined in the Safety Trial study table.",[54],"Early Stage Non-Small Cell Lung Cancer","RECRUITING","2026-01-13",{"date":58,"type":33},"2026-01-14",{"date":60,"type":33},"2019-03-05",{"date":62,"type":20},"2028-12-31",{"name":64,"class":65},"Abramson Cancer Center at Penn Medicine","OTHER",1,"Early Stage Non-small Cell Lung Cancer"]